We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New ICM Proactively Monitors Heart Patients at Risk

By HospiMedica International staff writers
Posted on 05 Jan 2021
A new implantable sensor monitors for early signs of potential life-threatening cardiac arrhythmias and body temperature increases potentially associated with fever.

The BIOTRONIK (Buelach, Switzerland) BIOMONITOR IIIm Vital Data Sensor is a programmable injectable cardiac monitor (ICM) designed to record subcutaneous electrocardiograms (ECGs) and other physiological parameters, including patient activity, heart rate, and body temperature. More...
By proactively monitoring the interrelationship between vital signs and health conditions, in particular fever, physicians can potentially provide earlier detection of infection, while streamlining remote patient management and preserving capacity in the hospital for the sickest patients.

Using two integrated electrodes, the BIOMONITOR IIIm records subcutaneous ECGs and sends them wirelessly to the BIOTRONIK Home Monitoring Service Center to record arrhythmias, including atrial fibrillation (AF), bradyarrhythmia, asystole, sudden rate drop, or high ventricular rate (HVR). The device can also be activated by the patients themselves to record cardiac rhythm during symptomatic episodes. The built-in battery provides 5.5 years of continuous monitoring, aiding long-term monitoring of chronic cardiac conditions.

BIOMONITOR IIIm also features BIOvector, a hybrid rigid/flexible design concept with a unique footprint that is designed to improve sensing, without sacrificing either patient comfort or cosmetic appearance. In addition to the small, flexible sensing antenna, BIOMONITOR III also takes advantage of a lossless compression algorithm that ensures that high amplitude signal quality is available anytime via the Home Monitoring system. In addition, intelligent memory management prevents the overwriting of clinically relevant episodes, improving diagnostic workflow performance.

“Vital data trends help support the diagnosis for a range of illnesses and, given the additional impact of the current pandemic on cardiac health, we have worked with urgency to advance BIOMONITOR IIIm's unique sensor technology,” said David Hayes, MD, chief medical officer of BIOTRONIK. “Patients with cardiac conditions are at an increased risk for worse outcomes from many systemic illnesses, so closer monitoring of these patients may help manage potential symptoms associated with a febrile response, particularly if it can be done safely and remotely.”

Related Links:
BIOTRONIK


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.